TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29154073

Group type: EXPERIMENTAL
Intervention: Aqueous extract of edible dried fig fruit applied twice a day for two weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydrocortisone 1.0% applied twice a day for two weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Base cream (placebo) applied twice a day for two weeks
Number of subjects: 45
Study: 26595347

Group type: EXPERIMENTAL
Intervention: Endoscopic decompression (n = 29)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Open decompression (n = 27)
Number of subjects: 54
Study: 23889837

Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT): 100 hours of speech and language therapy (2 hours per day, 5 days per week for 10 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular Treatment (RT): 100 hours of speech and language therapy (2 hours per week for 50 weeks)
Number of subjects: 30
Study: 21510321

Group type: EXPERIMENTAL
Intervention: Lafutidine with peppermint oil (10 mg lafutidine + 0.64 mL peppermint oil)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lafutidine alone (10 mg)
Number of subjects: 10
Study: 19783777

Group type: EXPERIMENTAL
Intervention: LTP
Number of subjects: 55
Study: 16449995

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a (3 megaunits three times per week for 2 years or until recurrence)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo (OBS group)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a
Number of subjects: 674
Study: 15265090

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 18
Study: 11682352

Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9644643

Group type: EXPERIMENTAL
Intervention: Thrombophilia (inherited or acquired risk factors)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No thrombophilia
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Thrombophilia
Number of subjects: 97

Group type: COMPARATOR
Intervention: Normal hemostasis parameters
Number of subjects: 97
Study: 7512335

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation for subfoveal CNV
Number of subjects: 289
Study: 3415805

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg bid for 6 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13
Study: 29722602

Group type: COMPARATOR
Intervention: Active IFC + laser sham (G1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: IFC sham + active laser (G2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Active IFC + laser (G3)
Number of subjects: 168

Group type: COMPARATOR
Intervention: IFC + laser sham (G4)
Number of subjects: 168
Study: 28259776

Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Efavirenz (600 mg), Emtricitabine (200 mg), Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Rilpivirine, Emtricitabine, Tenofovir alafenamide
Number of subjects: 875

Group type: COMPARATOR
Intervention: Efavirenz, Emtricitabine, Tenofovir disoproxil fumarate
Number of subjects: 875
Study: 25096954

Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 400

Group type: COMPARATOR
Intervention: No Partogram
Number of subjects: 400
Study: 23884300

Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted imaging (WB-DWI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted imaging + whole-body contrast-enhanced magnetic resonance imaging (WB-DWI + WB-ceMRI)
Number of subjects: 19
Study: 22011796

Group type: EXPERIMENTAL
Intervention: Augmented low-dye (ALD) taping
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Heel-pain orthosis (HPO)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 18276188

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (5 hours per night for four consecutive days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alcohol intake (BAC around 0.4-0.6 per thousand)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoxia (13% O2 concentration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recovery (8 hours of sleep)
Number of subjects: 16
Study: 17416006

Group type: EXPERIMENTAL
Intervention: 250 ml/d amino acids PN therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 500 ml/d amino acids PN therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no amino acids PN therapy)
Number of subjects: 72
Study: 14687310

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement providing the reference nutrient intake for all vitamins and trace elements
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 11560718

Group type: EXPERIMENTAL
Intervention: Day hospital rehabilitation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Social services day centres augmented by visiting therapists
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Day centre model
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Collaborative working in day centres
Number of subjects: 105
Study: 9164880

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with angina and normal coronary arteries
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy postmenopausal women (Control)
Number of subjects: 47
Study: 7956393

Group type: EXPERIMENTAL
Intervention: OKY-046 (200 mg twice a day for 3 days, 200 mg on the fourth day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3372915

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic steroids pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical steroids pretreatment
Number of subjects: 0
Study: 31262641

Group type: EXPERIMENTAL
Intervention: Nebulized streptokinase (250,000 IU/4 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nebulized heparin (10,000 IU/4 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 60
Study: 30008280

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 0
Study: 28338362

Group type: EXPERIMENTAL
Intervention: T (50 mg/kg BM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C (5 mg/kg BM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C + T (5 mg/kg BM + 50 mg/kg BM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: P (5 mg/kg BM)
Number of subjects: 7
Study: 25515936

Group type: EXPERIMENTAL
Intervention: School-based educational programme (seven modules with activities, workshops, and class sessions)
Number of subjects: 2245

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2245
Study: 23108482

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 89
Study: 21418096

Group type: EXPERIMENTAL
Intervention: 6-month Diabetes Medication Assistance Service
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: 12-month Diabetes Medication Assistance Service
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Diabetes Medication Assistance Service (both 6 and 12 months)
Number of subjects: 524
Study: 18204348

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 to 0.4 mg/kg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22213489

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Home Exercise with Advice (HEA)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 272
Study: 15766585

Group type: COMPARATOR
Intervention: C‐SE non‐etch (mild self‐etch adhesive applied without selective etching)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: C‐SE etch (mild self‐etch adhesive applied with selective etching)
Number of subjects: 29
Study: 12364432

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10218691

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lidocaine 1.0%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% buffered to pH 7.0
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% diluted 1:1 with glutathione bicarbonate Ringer solution
Number of subjects: 48
Study: 7828384

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Propranolol (80 mg/day)
Number of subjects: 53
Study: 2225899

Group type: EXPERIMENTAL
Intervention: Acrylic palatal stabilizing device (PSD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no PSD)
Number of subjects: 26
Study: 755862

Group type: EXPERIMENTAL
Intervention: Fading plus feedback training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 12045410

Group type: EXPERIMENTAL
Intervention: Early life events (including prenatal factors, infections, diet, and allergen exposure)
Number of subjects: 0
Study: 31320354

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram with pacemaker check
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Routine follow-up with pacemaker check alone
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: External validation of risk stratification model
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 1200
Study: 29868877

Group type: EXPERIMENTAL
Intervention: Increased direct supervision (attending physicians joined work rounds)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Standard supervision (attending physicians available but did not join work rounds)
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Increased direct supervision
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Standard supervision
Number of subjects: 1259
Study: 26676309

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (Minirin Melt) 60 μg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (Minirin Melt) 120 μg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Combination of 30 mg im ketorolac and 60 μg sublingual desmopressin
Number of subjects: 249

Group type: COMPARATOR
Intervention: Ketorolac tromethamine (30 mg im)
Number of subjects: 249

Group type: COMPARATOR
Intervention: NSAID group (ketorolac)
Number of subjects: 249
Study: 24872119

Group type: EXPERIMENTAL
Intervention: Peer adherence support intervention
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 340
Study: 22334420

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Crossover to femoral
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Operator-reported subclavian tortuosity
Number of subjects: 1000
Study: 20933145

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) for 15 minutes, 5 times a week for 1 month
Number of subjects: 16

Group type: COMPARATOR
Intervention: Social visits for 15 minutes, 5 times a week for 1 month
Number of subjects: 16
Study: 17682938

Group type: EXPERIMENTAL
Intervention: Non‐occupational post‐exposure prophylaxis (NPEP)
Number of subjects: 0
Study: 15673854

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 96
Study: 12923444

Group type: EXPERIMENTAL
Intervention: Resistance exercise on a lumbar extensor machine for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study: 10479611

Group type: EXPERIMENTAL
Intervention: Brief phone counseling (up to two short calls)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Brief phone counseling
Number of subjects: 714
Study: 9023388

Group type: EXPERIMENTAL
Intervention: Bepanthen cream applied to randomly selected parts of treatment fields
Number of subjects: 86

Group type: COMPARATOR
Intervention: No topical ointment (control)
Number of subjects: 86
Study: 2003042

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (300 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6370439

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1,200 mg once daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 100 mg four times daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 30801370

Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Augmented External Fixation (EF)
Number of subjects: 166
Study: 29786537

Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 190

Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 190
Study: 27484605

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon Q™)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional ligating brackets (Mini Master Series)
Number of subjects: 15
Study: 24587262

Group type: EXPERIMENTAL
Intervention: Voriconazole (VCZ)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 147
Study: 21741739

Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgical curettage
Number of subjects: 50
Study: 20101773

Group type: COMPARATOR
Intervention: Endoscopy-based long-term study
Number of subjects: 10
Study: 17585059

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid
Number of subjects: 476
Study: 15826468

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (younger patients under 55 years)
Number of subjects: 24
Study: 12056707

Group type: EXPERIMENTAL
Intervention: Oral capecitabine (1250 mg/m2 twice daily, on days 1‐14 every 21 days)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Intravenous 5‐FU/leucovorin (Mayo Clinic regimen)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Intravenous 5‐FU/leucovorin
Number of subjects: 1207
Study: 10496113

Group type: EXPERIMENTAL
Intervention: CES plus low dose caffeine (150 mg/l)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CES plus medium dose caffeine (225 mg/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CES placebo (68.8 g/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 15
Study: 7778921

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 epinephrine (n = 39)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1% lidocaine (n = 33)
Number of subjects: 72
Study: 1964620

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg four times daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6162280

Group type: EXPERIMENTAL
Intervention: Irradiation therapy combined with vitamin A palmitate (1.5 million IU/day; total dose 30 million IU), applied orally
Number of subjects: 42

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Irradiation therapy combined with vitamin A palmitate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 42
Study: 30692558

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in fasted condition
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in high-fat/low-caloric condition
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in high-fat/high-caloric breakfast
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (A-L) in fed state
Number of subjects: 287

Group type: COMPARATOR
Intervention: Moxifloxacin (placebo-controlled)
Number of subjects: 287
Study: 28122892

Group type: EXPERIMENTAL
Intervention: alemtuzumab 30 mg by intravenous infusion every other day three times a week for 12 weeks
Number of subjects: 6
Study: 26100413

Group type: EXPERIMENTAL
Intervention: Once monthly administration of vitamin D3 (25,000 IU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Daily administration of a fixed-dose combination of vitamin D3 (800 IU) and calcium (1000 mg)
Number of subjects: 100
Study: 24045936

Group type: EXPERIMENTAL
Intervention: Native tissue vs. graft-augmented rectocele repair (specific intervention details not provided)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Postoperative defecatory or incontinence symptoms
Number of subjects: 125
Study: 23008077

Group type: EXPERIMENTAL
Intervention: Personalized prescribing portrait on statins with therapeutic recommendations (intervention group)
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Delayed control group (control group)
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Personalized prescribing portrait on statins (intervention group)
Number of subjects: 2725
Study: 19386747

Group type: EXPERIMENTAL
Intervention: Lower protein formula (1.77 and 2.2 g protein/100 kcal)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Higher protein formula (2.9 and 4.4 g protein/100 kcal)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Breastfed group
Number of subjects: 1138
Study: 17244173

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15660234

Group type: EXPERIMENTAL
Intervention: Continuous SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cyclic SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cyclic SCT nasal spray on 10 days consecutively per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120
Study: 12814035

Group type: EXPERIMENTAL
Intervention: G115 100 mg bid for three months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 10417580

Group type: EXPERIMENTAL
Intervention: 70% glycolic acid
Number of subjects: 26

Group type: COMPARATOR
Intervention: Jessner's solution
Number of subjects: 26
Study: 8824658

Group type: EXPERIMENTAL
Intervention: Morning dosage of 40 mg omeprazole
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Evening dosage of 40 mg omeprazole
Number of subjects: 17
Study: 2200557

Group type: EXPERIMENTAL
Intervention: Upper midline incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transverse incision
Number of subjects: 0
Study: 7012189

Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kaopectate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 30853771

Group type: EXPERIMENTAL
Intervention: Active CAMBRA treatment
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 460
Study: 27889837

Group type: EXPERIMENTAL
Intervention: Exercise training intervention (12 weeks of supervised, progressive treadmill walking)
Number of subjects: 8
Study: 26927479

Group type: EXPERIMENTAL
Intervention: APOLO-Bari program for one year in addition to treatment as usual
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study: 24433229

Group type: EXPERIMENTAL
Intervention: Social media recruitment strategies (Facebook and Twitter)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Online survey
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Email, phone, and text message contact
Number of subjects: 751

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 751
Study: 21921821

Group type: EXPERIMENTAL
Intervention: Short-sprint training (SST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-sprint training (LST)
Number of subjects: 30
Study: 19324332

Group type: EXPERIMENTAL
Intervention: Adult learners presented with scattered inconsistency in determiners.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adult learners with low frequency determiners in consistent contexts.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child learners compared to adult learners.
Number of subjects: 0
Study: 17300357

Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15080022

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 101
Study: 12772414

Group type: EXPERIMENTAL
Intervention: CTP combined with dexamethasone (DXM)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (traditional methods including hyperbaric oxygen, vasodilator, energy preparation such as ATP, CoA, and dexamethasone)
Number of subjects: 207
Study: 11377920

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16